Compare Datadog Inc (DDOG) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Quest Diagnostics Inc — how do they compare? Datadog Inc trades at $272.1 (market cap $96.37B), while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Datadog Inc is far larger — about 4.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| DDOG | DGX | |
|---|---|---|
Market Cap | $96.37B | $22.80B |
Sector | Technology | Health |
52-Week High | $277.49 | $216.02 |
52-Week Low | $102.62 | $166.42 |
Enterprise Value | $92.90B | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $260.24, up 1.05% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.58. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margin is modest at 3.69%. The company's acquisition of Adaptive ML aims to bolster its AI capabilities, positioning it for sustained growth in cloud observability.
The outlook for DDOG is positive, driven by solid revenue expansion and strategic AI investments, but high valuation multiples (P/E of 667.28, P/S of 25.79) pose risks if growth slows. Investor sentiment is overwhelmingly bullish, with 83% of analysts rating it a buy, though competition and market volatility require monitoring. The stock's momentum and institutional backing suggest further upside, contingent on continued execution and market conditions.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
